CHEK2 and renal cell carcinoma: Of the 19 early onset (≤45 years) participants with a P/LP variant in an RCC-CSG, the majority were in VHL (n = 7), followed by CHEK2 (n = 3), FLCN (n = 2) and SDHB (n = 2).